• Caris Life Sciences published a study in Clinical Cancer Research examining molecular differences in ESR1-mutated metastatic breast cancer.
• Certain ESR1 variants, multiple mutations and lower estrogen receptor pathway activity were associated with shorter time on elacestrant treatment.
• Findings suggest comprehensive molecular profiling could provide information beyond mutation status alone, but require prospective validation before guiding clinical decisions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Caris Life Sciences Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.